INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sanofi - SNY

27.07.25 16:00 Uhr

Werte in diesem Artikel

NEW YORK, July 27, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Sanofi ("Sanofi" or the "Company") (NASDAQ: SNY).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.  

Fighting for victims of securities fraud for more than 85 years (PRNewsfoto/Pomerantz LLP)

The investigation concerns whether Sanofi and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. 

[Click here for information about joining the class action] 

On May 30, 2025, Sanofi issued a press release announced mixed data from a Phase 3 program for itepekimab, an antibody therapy targeting the lung disorder chronic obstructive pulmonary disease.  Although the AERIFY-1 late-stage trial met the primary endpoint with a statistically significant and clinically meaningful impact, the AERIFY-2 trial failed to reach the same goal. 

On this news, Sanofi's American Depositary Receipt ("ADR") price fell $2.98 per ADR, or 5.69%, to close at $49.37 per ADR on May 30, 2025.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, London, and Paris is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

Attorney advertising.  Prior results do not guarantee similar outcomes.  

CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-sanofi---sny-302512740.html

SOURCE Pomerantz LLP

In eigener Sache

Übrigens: Sanofi und andere US-Aktien sind bei finanzen.net ZERO sogar bis 23 Uhr handelbar (ohne Ordergebühren, zzgl. Spreads). Jetzt kostenlos Depot eröffnen und als Geschenk eine Gratisaktie erhalten.

Ausgewählte Hebelprodukte auf Sanofi

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Sanofi

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Nachrichten zu Sanofi S.A. (spons. ADRs)

Wer­bung

Analysen zu Sanofi S.A. (spons. ADRs)

DatumRatingAnalyst
01.11.2018Sanofi Equal WeightBarclays Capital
23.01.2018Sanofi UnderweightBarclays Capital
15.11.2017Sanofi Equal WeightBarclays Capital
06.04.2017Sanofi BuyArgus Research Company
DatumRatingAnalyst
06.04.2017Sanofi BuyArgus Research Company
DatumRatingAnalyst
01.11.2018Sanofi Equal WeightBarclays Capital
15.11.2017Sanofi Equal WeightBarclays Capital
DatumRatingAnalyst
23.01.2018Sanofi UnderweightBarclays Capital

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Sanofi S.A. (spons. ADRs) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen